$CSTL News

Castle Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Baird Maintains Outperform on Castle Biosciences, Lowers Price Target to $43

Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript

Castle Biosciences, Inc. Q1 2026 Earnings Call Summary

Castle Biosciences Q1 Earnings Call Highlights

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences Inc (NASDAQ:CSTL) Beats Q1 Estimates, Raises Full-Year Guidance

Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences Raises FY2026 Sales Guidance from $340.000M-$350.000M to $345.000M-$355.000M vs $345.734M Est

Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus